首页|载药微球联合碘化油经导管动脉化疗栓塞术及阿帕替尼治疗原发性肝癌的疗效

载药微球联合碘化油经导管动脉化疗栓塞术及阿帕替尼治疗原发性肝癌的疗效

扫码查看
目的 探讨载药微球联合碘化油经导管动脉化疗栓塞术(TACE)及阿帕替尼对原发性肝癌(PHC)的疗效.方法 选取符合标准的136例PHC患者分为两组,研究组(n = 89)采用载药微球联合碘化油TACE及阿帕替尼治疗;对照组(n = 47)采用碘化油TACE联合阿帕替尼治疗,比较两组疗效、肝功能、肿瘤相关指标、不良反应、预后情况的差异.结果 在治疗前,各项指标差异不具有统计学意义(P>0.05).治疗后研究组疾病控制率高于对照组(98.8%vs 83.0%)(P<0.05);治疗后两组肝功能指标均较治疗前升高[TBIL(25.9±3.6)vs(25.6±3.5)μmol·L-1,ALT(72.5±7.6)vs(71.9±7.2)U·L-1,AST(58.5±4.6)vs(58.8±4.2)U·L-1](t = 3.326、3.219,4.182,4.110,3.281,3.261,P = 0.032,0.036,0.027,0.030,0.032,0.035),组间差异不具有统计学意义(t = 1.282、1.227,1.362,P = 0.288,0.182,0.362);治疗后研究组肿瘤指标改善更甚[HIF-1α(112.1±16.2)vs(158.8±18.4)pg·mL-1,AFP(130.1±22.2)vs(192.4±29.4)ng·mL-1](t = 3.330、4.315,P = 0.037,0.025);治疗后两组的不良反应发生率比较差异不具有统计学意义(P>0.05);术后研究组的总生存率高于对照组(80.9%vs 63.8%)(P<0.05).结论 载药微球联合碘化油TACE及阿帕替尼对PHC患者的疗效较佳,同时不增加肝毒性及不良反应率,并利于预后改善.
Efficacy of drug-loaded microspheres combined with iodinated oil TACE and apatinib in the treatment of primary liver cancer
Objective To investigate the efficacy of drug-loaded microspheres combined with transcatheter arterial chemoembolisation with iodinated oil(transarterial chemoembolization,TACE)and apatinib in primary hepatocellular carcinoma(primary hepatic carcinoma,PHC).Methods A total of 136 PHC patients meeting the criteria were selected and divided into two groups.The study group(n = 89)was treated with drug-loaded microspheres in combination with iodinated oil TACE and apatinib.The control group(n = 47)was treated with iodinated oil TACE combined with apatinib.Differences in efficacy,liver function,tumour-related indexes,adverse reactions,and prognosis were compared between the 2 groups.Results Before treatment,the differences in the indicators were not of statistical interest(P>0.05).Liver function indices were higher in both groups after treatment compared to before treatment[TBIL(25.9±3.6)vs(25.6±3.5)μmol·L-1,ALT(72.5±7.6)vs(71.9±7.2)U·L-1,AST(58.5±4.6)vs(58.8±4.2)U·L-1](t = 3.326、3.219,4.182,4.110,3.281,3.261,P = 0.032,0.036,0.027,0.030,0.032,0.035),but the difference between groups was not statistically significant(t = 1.282、1.227,1.362,P = 0.288,0.182,0.362).Improvement in tumour indices was even greater in the study group after treatment[HIF-1α(112.1±16.2)vs(158.8±18.4)pg·mL-1,AFP(130.1±22.2)vs(192.4±29.4)ng·mL-1](t = 3.330、4.315,P = 0.037,0.025).The adverse event rate of the two groups after therapy was not significant(P>0.05);the overall survival rate of the study group was higher than that of the control group after the operation(80.9%vs.63.8%)(P<0.05).Conclusion Drug-eluting microspheres combined with iodized oil TACE and apatinib showed better efficacy in patients with PHC without increasing liver toxicity or adverse reactions.It also contributed to the improvement of prognosis.

Primary hepatocellular carcinomaTransarterial chemoembolizationDrug-eluting microspheresIodized oilApatinib

薛凤华、朱琳、张舒、张菲菲、王庆东、张超

展开 >

临沂市肿瘤医院,临沂 276000

上海同济大学医学院,上海 200082

山东大学齐鲁医院,济南 250031

原发性肝癌 经导管肝动脉化疗栓塞术 载药微球 碘化油 阿帕替尼

山东省临沂市科技发展计划

202120025

2024

中国药物应用与监测
中国人民解放军总医院

中国药物应用与监测

CSTPCD
影响因子:1.983
ISSN:1672-8157
年,卷(期):2024.21(1)
  • 20